Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma

What Was Tested

In this phase 2 trial, researchers set out to test Romiplostim.

The purpose of this study is to see if the study drug, romiplostim, helps low platelet count caused by standard chemotherapy treatment for lymphoma.

It had 1 arm (groups): romiplostim (experimental).

The registry classes the interventions as drug.

Who Took Part

The registry lists 11 actual participants took part.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Adult patients ≥ 18 years old diagnosed with any type of lymphoma. History of a severe treatment-related thrombocytopenia during the most recent cycle of treatment, as defined by one or more of the following criteria:. PLT \< 50,000 on day 1 (- 2 days) of the subsequent treatment cycle. Patient is planned for at least one more cycle of chemotherapy. Patients must have normal organ function as defined below on day 1 of the prior cycle:.

The full record lists 15 inclusion and 13 exclusion criteria; among the exclusions: history of allogeneic hematopoietic stem cell transplantation (sct). patients with a prior autologous sct or car-t treatment are eligible; patients who have thrombocytopenia related to pre-existing itp; major surgery within 26 days prior to enrollment, or minor surgery within 3 days prior to enrollment.

How the Study Was Run

It was run as a single-group and open-label study.

Everyone knew when Romiplostim was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2020-12-14 with completion listed for 2026-04-07.

It ran at 7 sites in United States (7).

Its stated primary purpose is treatment.

What This Means in Plain Language

Put simply, this is a phase 2 trial of Romiplostim in 11 people.

Its size is small, so on its own it can only give an early look.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Romiplostim compound page, all human trials.